Safety and pharmacokinetics of palivizumab, administered in infants with a history of prematurity or chronic lung disease

Japanese Journal of Chemotherapy

Volumn 50, Issue 4, 2002, Pages 215-222

  Takeuchi, Yoshinao ^a   Cho, Hideo ^a   Yamashita, Yukio ^a   Mishiku, Yuriko ^a   Nakao, Ayumi ^a   Aso, Taiji ^a   Nishida, Hiroshi ^a   Takahashi, Naoto ^a   Sakuma, Izumi ^a   Kawakami, Tadashi ^a   Yoda, Hitoshi ^a   Mugishima, Hideo ^a   Minato, Michiyoshi ^a   Taguchi, Masanori ^a   Shimada, Masami ^a   Takekuma, Koji ^a   Takei, Akito ^a   Takami, Tsuyoshi ^a   Ogawa, Yunosuke ^a   Shimizu, Hiroshi ^a   Takada, Eiko ^a   Itabashi, Kazuo ^a   Itakura, Yoshino ^a   Nakamura, Toshihiko ^a   Kusuda, Satoshi ^a   Kim, Tashou ^a   Shishida, Norio ^a   Miyagi, Nobuhiro ^a   more..

^a KAWASAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Palivizumab; Respiratory syncytial virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MONOCLONAL ANTIBODY; PALIVIZUMAB;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; ECZEMA; FEMALE; FEVER; GESTATION PERIOD; HUMAN; IMMUNOGENICITY; INFANT; LABORATORY TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; MALE; PREMATURITY; PROTEIN URINE LEVEL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RHINITIS; TACHYCARDIA; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 0036109682     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Respiratory Syncytial Virus: What we know now
2. Primary infection and reinfection with respiratory syncytial virus
3. Epidemiological and clinical features of influenza and respiratory syncytial virus infection among children in Japan
4. Respiratory syncytial virus infection in lower respiratory tract and asthma attack in hospitalized children in Hokkaido, Japan
5. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation
6. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
7. Respiratory syncytial virus infection in infants with congenital heart disease
8. Respiratory syncytial virus in immunocompromised children
9. Respiratory virus immunization. A field trial of two inactivated respiratory virus vaccine
10. An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children respiratory vaccinated with an inactivated RSV vaccine
11. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
12. "Respiratory Syncytial Virus"
13. The G-glycoprotein of human respiratory syncytial viruses of subgroup A and B. Extensive sequence divergence between antigenically related proteins
14. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children
15. Protective epitope on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal Antibody
16. Monoclonal antibody-resistant mutants selected with a respiratory virus - Neutralizing human antibody Fab Fragment (Fab 19). Define a unique epitope on the fusion (F) glycoprotein
17. Development of humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
18. Quantitative aspect of passive immunity to respiratory syncytial virus infection in cotton rats
19. Comparison of antibody concentration and protective antibody of respiratory syncytial virus immuno globulin and conventional immune globulin
20. Standard (IGIV) vs RSV enriched (RSVIG) intravenous immuno globulin for RSV immunoprophylaxis
21. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
22. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
23. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
24. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
25. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
26. Development of the immune system in very low birth weight (less than 1500 g) premature infants: Concentrations of plasma immunoglobulins and pattern of infection
27. Respiratory syncytial virus-specific immunoglobulin in preterm infants